Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | No Grouping
Number of items: 11.

Journal Article

Lavezzi, Silvia Maria, de Jong, Jan, Neyens, Martine, Cramer, Paula, Demirkan, Fatih ORCID: 0000-0002-1172-8668, Fraser, Graeme, Bartlett, Nancy ORCID: 0000-0001-8470-394X, Dilhuydy, Marie-Sarah, Loscertales, Javier, Avigdor, Abraham, Rule, Simon, Samoilova, Olga, Goy, Andre ORCID: 0000-0001-5125-6522, Ganguly, Siddhartha, Salman, Mariya, Howes, Angela, Mahler, Michelle, De Nicolao, Giuseppe and Poggesi, Italo (2019). Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial. Pharm. Res., 36 (7). NEW YORK: SPRINGER/PLENUM PUBLISHERS. ISSN 1573-904X

Hallek, Michael, Fraser, Graeme, Cramer, Paula, Demirkan, Fatih ORCID: 0000-0002-1172-8668, Silva, Rodrigo Santucci, Grosicki, Sebastian, Janssens, Ann, Pristupa, Aleksander, Mayer, Jiri, Dilhuydy, Marie Sarah, Loscertales, Javier, Bartlett, Nancy, Avigdor, Abraham, Rule, Simon, Sun, Steven, Mahler, Michelle, Phelps, Charles, Salman, Mariya, Howes, Angela and Chanan-Khan, Asher (2017). Three-year follow-up of patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) receiving ibrutinib plus bendamustine and rituximab (BR) versus placebo plus BR: an update of the HELIOS study. Leuk. Lymphoma, 58. S. 192 - 195. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Kipps, Thomas J., Hillmen, Peter, Demirkan, Fatih ORCID: 0000-0002-1172-8668, Grosicki, Sebastian, Coutre, Steven E., Barrientos, Jacqueline C., Barr, Paul M., Janssens, Ann, Byrd, John C., O'Brien, Susan M., Fraser, Graeme, Jaeger, Ulrich, Cramer, Paula, Stilgenbauer, Stephan, Chanan-Khan, Asher A., Salman, Mariya, Solman, Isabelle, Cheng, Mei, Phelps, Charles, Ninomoto, Joi, Howes, Angela, James, Danelle F. and Hallek, Michael (2016). 11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies. Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Fraser, Graeme, Cramer, Paula, Demirkan, Fatih ORCID: 0000-0002-1172-8668, Silva, Rodrigo Santucci, Pylypenko, Halyna, Grosicki, Sebastian, Janssens, Ann, Pristupa, Aleksander, Mayer, Jiri, Dilhuydy, Marie-Sarah, Loscertales, Javier, Goy, Andre ORCID: 0000-0001-5125-6522, Avigdor, Abraham, Rule, Simon, Phelps, Charles, Mahler, Michelle, Salman, Mariya, Howes, Angela J., Balasubramanian, Sriram and Chanan-Khan, Asher Alban Akmal (2016). Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study. J. Clin. Oncol., 34 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Chanan-Khan, Asher, Cramer, Paula, Demirkan, Fatih ORCID: 0000-0002-1172-8668, Fraser, Graeme, Silva, Rodrigo Santucci, Grosicki, Sebastian ORCID: 0000-0003-2644-1050, Pristupa, Aleksander, Janssens, Ann, Mayer, Jiri, Bartlett, Nancy L., Dilhuydy, Marie-Sarah, Pylypenko, Halyna, Loscertales, Javier, Avigdor, Abraham, Rule, Simon, Villa, Diego, Samoilova, Olga, Panagiotidis, Panagiots, Goy, Andre ORCID: 0000-0001-5125-6522, Mato, Anthony, Pavlovsky, Miguel A., Karlsson, Claes, Mahler, Michelle, Salman, Mariya, Sun, Steven, Phelps, Charles, Balasubramanian, Sriram, Howes, Angela, Hallek, Michael, Assouline, S., Bence-Bruckler, I., Buckstein, R., Fraser, G., Larratt, L., Minuk, L., Villa, D., Angevine, A., Bartlett, N., Bixby, D., Caimi, P., Chanan-Khan, A., Craig, M., Forero-Torres, A., Ganguly, S., Goy, A., Heffner, L., Hermann, R., Lansigan, F., Leis, J., Letzer, J., Link, B., Liu, D., McCaul, K., McGuire, E., Skinner, W., Starodub, A., Stuart, R., Thirman, M., Tirumali, N., Yang, J., Janssens, A., Offner, F., Van den Neste, E., Van Hoof, A., Mayer, J., Novak, J., Trneny, M., Cartron, G., Dartigeas, C., Dilhuydy, M., Ghez, D., Haioun, C., Leblond, V., Salles, G., Balser, C., Cramer, P., Dreger, P., Durig, J., Eckart, M., Heinrich, B., Illmer, T., Jentsch-Ullrich, K., Pfreundschuh, M., Schetelig, J., Schlag, R., Soling, U., Stilgenbaue, S., Anagnostopoulos, A., Dimopoulos, A., Panagiotidis, P., Vrakidou, E., Bairey, O., Ben Yehuda, D., Braester, A., Fineman, R., Herishanu, Y., Nagler, A., Ruchlemer, R., Tadmor, T., Grosicki, S., Homenda, W., Jurczak, W., Pluta, A., Woszczyk, D., Espirito Santo, A., Luis, R., Raposo, J., Viveiros, C., Alexeeva, J., Dunaev, Y., Golubeva, M., Khuageva, N., Loginov, A., Lysenko, I., Osmanov, E., Pavlov, V., Pristupa, A., Proydakov, A., Rossiev, V., Samarina, I., Samoilova, O., Serduk, O., Shneider, T., Udovitsa, D., Voloshin, S., Gayoso, J., Gonzalez, M., Gonzalez Barca, E., Hernandez Rivas, J., Jargue, I., Loscertales, J., Karlsson, C., Sender, M., Aktan, M., Arslan, O., Demirkan, F., Ferhanoglu, B., Kaynar, L., Sayinalp, N., Vaural, F., Yagci, M., Dyagil, I., Kaplan, P., Masliak, Z., Oliynyk, H., Popovska, T., Pylypenko, H., Rekhtman, G., Dearden, C., Morley, N., Moss, P., Rule, S., Pavlovsky, M., Riveros, D., Santucci-Silva, R., Romeo, M., Scheliga, A., Salazar, L., Gomez, D., Ramirez, E. and Jung, C. (2016). Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol., 17 (2). S. 200 - 212. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Chanan-Khan, Asher Alban Akmal, Cramer, Paula, Demirkan, Fatih ORCID: 0000-0002-1172-8668, Fraser, Graeme, Silva, Rodrigo Santucci, Pylypenko, Halyna, Grosicki, Sebastian, Janssens, Ann, Pristupa, Alexander, Mayer, Jiri, Dilhuydy, Marie-Sarah, Loscertales, Javier, Bartlett, Nancy L., Avigdor, Abraham, Rule, Simon, Sun, Steven, Mahler, Michelle, Salman, Mariya, Howes, Angela J. and Hallek, Michael J. (2015). Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study. J. Clin. Oncol., 33 (18). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Cramer, Paula, Chanan-Khan, Asher, Fraser, Graeme, Demirkan, Fatih ORCID: 0000-0002-1172-8668, Silva, Rodrigo Santucci, Pylypenko, Halyna, Grosicki, Sebastian, Janssens, Ann, Pristupa, Aleksander, Goy, Andre ORCID: 0000-0001-5125-6522, Mayer, Jiri, Dilhuydy, Marie-Sarah, Loscertales, Javier, Barlett, Nancy, Avigdor, Abraham, Rule, Simon, Sun, Steven, Phelps, Charles, Mahler, Michelle, Salman, Masha, Howes, Angela and Hallek, Michael (2015). Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): safety analysis in the HELIOS trial. Leuk. Lymphoma, 56. S. 93 - 95. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Fraser, Graeme, Chanan-Khan, Asher, Cramer, Paula, Demirkan, Fatih ORCID: 0000-0002-1172-8668, Silva, Rodrigo Santucci, Pylypenko, Halyna, Grosicki, Sebastian, Janssens, Ann, Pristupa, Aleksander, Goy, Andre ORCID: 0000-0001-5125-6522, Mayer, Jiri, Dilhuydy, Marie-Sarah, Loscertales, Javier, Bartlett, Nancy, Avigdor, Abraham, Rule, Simon, Sun, Steven, Phelps, Charles, Mahler, Michelle, Salman, Masha, Howes, Angela and Hallek, Michael (2015). Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): subgroup efficacy analyses from the HELIOS trial. Leuk. Lymphoma, 56. S. 98 - 101. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Chanan-Khan, Asher, Fraser, Graeme, Cramer, Paula, Demirkan, Fatih ORCID: 0000-0002-1172-8668, Silva, Rodrigo Santucci, Pylypenko, Halyna, Grosicki, Sebastian, Janssens, Ann, Pristupa, Aleksander, Goy, Andre ORCID: 0000-0001-5125-6522, Mayer, Jiri, Dilhuydy, Marie-Sarah, Loscertales, Javier, Bartlett, Nancy, Avigdor, Abraham, Rule, Simon, Sun, Steven, Phelps, Charles, Mahler, Michelle, Salman, Masha, Howes, Angela and Hallek, Michael (2015). Ibrutinib combined with bendamustine/rituximab (BR) in previously treated small lymphocytic lymphoma (SLL): analysis of patients in the HELIOS trial. Leuk. Lymphoma, 56. S. 92 - 94. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Cramer, Paula, Chanan-Khan, Asher, Fraser, Graeme, Demirkan, Fatih ORCID: 0000-0002-1172-8668, Silva, Rodrigo Santucci, Pylypenko, Halyna, Grosicki, Sebastian, Janssens, Ann, Goy, Andre ORCID: 0000-0001-5125-6522, Mayer, Jiri, Dilhuydy, Marie Sarah, Loscertales, Javier, Bartlett, Nancy L., Avigdor, Abraham, Rule, Simon, Sun, Steven, Phelps, Charles, Mahler, Michelle, Salman, Mariya, Schaffer, Michael, Balasubramanian, Sriram, Howes, Angela and Hallek, Michael (2015). Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Chanan-Khan, Asher, Cramer, Paula, Demirkan, Fatih ORCID: 0000-0002-1172-8668, Fraser, Graeme, Silva, Rodrigo Santucci, Pylypenko, Halyna, Grosicki, Sebastian, Janssens, Ann, Pristupa, Aleksander, Goy, Andre ORCID: 0000-0001-5125-6522, Mayer, Jiri, Dilhuydy, Marie Sarah, Loscertales, Javier, Bartlett, Nancy L., Avigdor, Abraham, Rule, Simon, Sun, Steven, Phelps, Charles, Mahler, Michelle, Salman, Mariya, Howes, Angela and Hallek, Michael (2015). Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

This list was generated on Fri Aug 19 09:15:58 2022 CEST.